Chemoproteomics Market Report 2026

Chemoproteomics Market Overview

• Chemoproteomics market size has reached to $1.77 billion in 2025 • Expected to grow to $3.36 billion in 2030 at a compound annual growth rate (CAGR) of 13.7% • Growth Driver: Growing Demand For Personalized Medicine Driving The Market Growth Due To Advances In Genomic Technologies And Molecular Diagnostics • Market Trend: Innovative Live-Cell Platforms Revolutionize Early-Stage Drug Discovery • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Chemoproteomics Market?

Chemoproteomics is a branch of proteomics that uses chemical probes to systematically study the interactions, functions, and modifications of proteins within complex biological systems. It enables the identification of drug targets, protein–ligand interactions, and the mapping of reactive sites across the proteome. The main technologies of chemoproteomics include activity based protein profiling, quantitative proteomics, structural proteomics, affinity based protein profiling, and label free and isotope labeling techniques. Activity-based protein profiling (ABPP) is a technique that uses chemical probes to selectively label and measure the functional activity of enzymes in complex biological samples. The various product types include reagents and kits, instruments, software, and services. The key applications of drug discovery, target identification and validation, biomarker discovery, proteome profiling, and other application, while the end-use includes pharmaceutical and biotechnology companies, academic and research institutes, contract research organizations, and other end-user.

What Is The Chemoproteomics Market Growth Forecast?

The chemoproteomics market size is expected to see rapid growth in the next few years. It will grow to $3.36 billion in 2030 at a compound annual growth rate (CAGR) of 13.7%. The growth in the forecast period can be attributed to growing integration of AI in proteomics analysis, increasing demand for high-throughput chemoproteomics platforms, rising focus on personalized medicine, expansion of contract research organizations, increasing adoption of multi-omics approaches. Major trends in the forecast period include increasing adoption of activity-based protein profiling, rising demand for quantitative proteomics techniques, growing integration of structural proteomics approaches, expansion of affinity-based protein profiling applications, rising focus on label-free and isotope labeling techniques.

Global Chemoproteomics Market Segmentation

1) By Technology: Activity Based Protein Profiling, Quantitative Proteomics, Structural Proteomics, Affinity Based Protein Profiling, Label Free And Isotope Labeling Techniques 2) By Product Type: Reagents And Kits, Instruments, Software, Services 3) By Application: Drug Discovery, Target Identification And Validation, Biomarker Discovery, Proteome Profiling, Other Application 4) By End-User: Pharmaceutical And Biotechnology Companies, Academic And Research Institutes, Contract Research Organizations, Other End-User Subsegments: 1) By Activity Based Protein Profiling: Enzyme Activity Profiling, Covalent Probe Profiling, Targeted Activity Profiling, Functional Protein Profiling 2) By Quantitative Proteomics: Stable Isotope Labeling, Isobaric Tag Labeling, Label Free Quantification, Metabolic Labeling 3) By Structural Proteomics: X Ray Crystallography, Nuclear Magnetic Resonance, Cryogenic Electron Microscopy, Hydrogen Deuterium Exchange 4) By Affinity Based Protein Profiling: Protein Ligand Interaction, Antibody Based Capture, Small Molecule Affinity Capture, Protein Complex Isolation 5) By Label Free and Isotope Labeling Techniques: Label Free Mass Spectrometry, Isotope Coded Affinity Tagging, Dimethyl Labeling, Tandem Mass Tag Labeling

What Is The Driver Of The Chemoproteomics Market?

The growing demand for personalized medicine is expected to propel the growth of the chemoproteomics market going forward. Personalized medicine refers to medical treatments and therapies tailored to individual patients based on their genetic makeup, biomarkers, and specific disease characteristics. The demand for personalized medicine is rising due to advances in genomic technologies and molecular diagnostics, which allow doctors to tailor treatments specifically to a patient’s genetic profile and improve therapeutic outcomes. Chemoproteomics enables personalized medicine by identifying patient-specific protein–drug interactions and biomarker profiles, allowing tailored therapies that maximize efficacy and minimize adverse effects. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based non-profit organization, the Food and Drug Administration approved 16 new personalized treatments for rare disease patients in 2023, up from six in 2022, including seven cancer drugs and three for other diseases and conditions. Therefore, the growing demand for personalized medicine is driving the growth of the chemoproteomics industry.

Key Players In The Global Chemoproteomics Market

Major companies operating in the chemoproteomics market are Thermo Fisher Scientific Inc., Merck KGaA, Danaher Corporation, Agilent Technologies Inc., Shimadzu Corporation, PerkinElmer Inc., Bruker Corporation, Waters Corporation, Bio-Rad Laboratories Inc., Evotec SE, Promega Corporation, Cell Signaling Technology Inc., Seer Inc., ChomiX Biotech Inc., Abcam plc, Creative Proteomics Inc., MtoZ Biolabs Inc., Allumiqs Corporation, Dalriada Drug Discovery Ltd., MS Bioworks LLC.

Global Chemoproteomics Market Trends and Insights

Major companies operating in the chemoproteomics market are focusing on developing innovative solutions such as, live cell target engagement platforms, to accelerate drug discovery and improve early stage efficacy prediction. A live cell target engagement platform is a technology that measures how drug candidates interact with their molecular targets inside living cells in real time, providing more accurate and physiologically relevant data than traditional in vitro assays. For instance, in September 2025, LeadArt Biotechnologies Inc., a US-based biotechnology research company, launched its INTRAP platform, a next-generation live-cell target engagement and chemoproteomics system, at AHeDD 2025. The platform integrates chemoproteomics, automation, and AI to analyze drug-target interactions directly within living cells. This enables researchers to identify and optimize drug candidates more efficiently, particularly for challenging or “undruggable” targets. By providing real-time, physiologically relevant data, INTRAP aims to improve early-stage success rates and accelerate the overall drug discovery process.

What Are Latest Mergers And Acquisitions In The Chemoproteomics Market?

In March 2025, Momentum Biotechnologies, a US-based biotechnology company, acquired OmicScouts for an undisclosed amount. With this acquisition, Momentum Biotechnologies aims to enhance its technological capabilities in multi-omics data analysis and accelerate its drug discovery and development pipelines. OmicScouts GmbH is a Germany-based biotechnology company that specializes in providing extensive chemoproteomics services for drug discovery, focusing on target identification, selectivity profiling, and mechanism-of-action studies.

Regional Insights

North America was the largest region in the chemoproteomics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Chemoproteomics Market?

The chemoproteomics market consists of revenues earned by entities by providing services such as target identification and validation, protein–ligand interaction profiling, activity-based protein profiling, biomarker discovery and validation, and quantitative proteomics and chemoproteomic data analysis. The market value includes the value of related goods sold by the service provider or included within the service offering. The chemoproteomics market also includes sales of mass spectrometry instruments, liquid chromatography systems, bioinformatics and data analysis software, consumables and reagents, and automated sample preparation hardware. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data And Analysis Are Included In The Chemoproteomics Market Report 2026?

The chemoproteomics market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the chemoproteomics industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.